Michael Stocum, President and CEO: In his 25-plus year industry career, Michael has impacted products across several therapeutic areas, holding corporate roles in pharmaceuticals with GlaxoWellcome/GSK, biologics at Organon (now Merck) and molecular diagnostics at Organon Teknika (now bioMerieux) plus three biotech start-ups. He has also operated a life sciences consulting services company he founded in 2004.

A two-time CEO (Inivata and On-Q-ity), his roles have spanned bench research to product, business and commercial development. Throughout his career, he has delivered to market or enhanced the development of numerous medicines in several disease areas including cancer (Onco-TICE BCG, Tykerb/Tyverb and Votrient), infectious diseases (abacavir in multiple fixed-dose drug formulations) and cardiometabolic diseases (Avandia) along with multiple innovative molecular testing products such circulating tumor DNA (ctDNA) liquid biopsy, circulating tumor cells (CTCs), HIV-1 RNA and HBV DNA viral load tests. In 2004 Michael founded Personalized Medicine Partners (PMP) to provide global strategic business consulting and operational capabilities for biopharmaceutical, diagnostic and research/clinical services companies, specializing in product development and commercialization of integrated therapeutic and biomarker/companion diagnostic programs. Michael and his network that supports PMP has been instrumental in founding and providing executive management to several companies, including most recently, Inivata, a company spun out of the University of Cambridge (UK) in 2014 that is currently commercializing its lung cancer product in the US market. He is currently exploring opportunities to create a new innovative cancer therapeutic company to transform patient care.

Michael is the founding and past chair of the Personalized Medicine Division of the American Association for Clinical Chemistry and has been dedicated to advancing the field of Personalized Medicine. He has also served or is currently serving on several Company Boards, is an industry advisor to the Professional Sciences Masters in Microbial Biotechnology program at NC State University (NCSU) and recently joined the Center for Innovation Management Studies at NCSU as an Industrial Fellow.

Michael earned dual B.S. degrees in Biochemistry and Microbiology from NCSU, with a minor in Genetics and a Masters in Biotech Management, now a cornerstone of the MBA program in the College of Management that was created in the years following his graduation in 1992.